{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T00:24:00Z","timestamp":1794702240140,"version":"4.9.1"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"KI Research Grants","award":["024-02570"],"award-info":[{"award-number":["024-02570"]}]},{"name":"\u00ecShizu Matsumura\u00ees Donation","award":["2024-02228"],"award-info":[{"award-number":["2024-02228"]}]},{"name":"Swedish Research Council","award":["2024-06592"],"award-info":[{"award-number":["2024-06592"]}],"id":[{"id":"https:\/\/ror.org\/03zttf063","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det om H\u00e4lsa, Arbetsliv och V\u00e4lf\u00e4rd","doi-asserted-by":"publisher","award":["2022-01111"],"award-info":[{"award-number":["2022-01111"]}],"id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Research Council","award":["2024-02766"],"award-info":[{"award-number":["2024-02766"]}],"id":[{"id":"https:\/\/ror.org\/03zttf063","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2026,3,8]]},"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Attention-deficit\/hyperactivity disorder (ADHD) and substance use disorder (SUD) often coexist. ADHD complicates the course of disease in SUD. While recommended in guidelines, ADHD medication for those with comorbid SUD remains controversial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to explore how comorbid SUD affects ADHD medication discontinuation and reinitiation in individuals with ADHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a matched cohort design, we identified 9283 individuals with ADHD and SUD in Sweden between 2006 and 2020, who had ongoing ADHD medication at the time of their first SUD-related event. Controls with ADHD medication but no SUD (n=46 401) were matched 5:1 on sex and birth year. HRs for treatment discontinuation within 1 year from first SUD, and for treatment reinitiation within 1 year from the first discontinuation, were estimated using stratified Cox models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Individuals with ADHD and SUD were nearly two times as likely to discontinue ADHD treatment within 1 year (HR: 1.99, 95%\u2009CI 1.92 to 2.07)\u2009and less likely to re-initiate ADHD treatment (HR: 0.82, 95%\u2009CI 0.76 to 0.89) compared with controls. Several factors, including male sex, adolescent to young adult age and lower stimulant medication dose, were associated with increased risk for treatment discontinuation, but only adolescent to young adult age was significantly associated with treatment reinitiation in those with ADHD and SUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results suggest less treatment continuity and access for those with ADHD and comorbid SUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical implications<\/jats:title>\n                    <jats:p>Treatment providers need to consider the specific needs of individuals with ADHD and comorbid SUD, especially in young males, to improve treatment outcomes for vulnerable groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2025-302138","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:10:20Z","timestamp":1774282220000},"page":"e302138","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Discontinuation and reinitiation of pharmacological treatment for ADHD among individuals with ADHD and substance use disorder"],"prefix":"10.1136","volume":"29","author":[{"given":"Andrea J","family":"Capusan","sequence":"first","affiliation":[{"name":"Center for Social and Affective Neuroscience, Department of Biomedical and Clinical Sciences, Link\u00f6ping University, Link\u00f6ping, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7290-5103","authenticated-orcid":false,"given":"Le","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Public Health, Shenzhen University, Shenzhen, Guangzhou, People's Republic of China"},{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Larsson","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"School of Medical Sciences, \u00d6rebro University, \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3800-6665","authenticated-orcid":false,"given":"Isabell","family":"Brikell","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Biomedicine, Aarhus University, Aarhus, Denmark"},{"name":"Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Martinez","sequence":"additional","affiliation":[{"name":"Division on Substance Use Disorders, New York State Psychiatric Institute, New York, New York, USA"},{"name":"Department of Psychiatry, Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M","family":"D\u2019Onofrio","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Psychological and Brain Sciences, Indiana University Bloomington, Bloomington, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Lichtenstein","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3765-2067","authenticated-orcid":false,"given":"Ralf","family":"Kuja-Halkola","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8087-1417","authenticated-orcid":false,"given":"Zheng","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"2026091806102662000_29.1.e302138.1","doi-asserted-by":"publisher","DOI":"10.1111\/add.12370"},{"key":"2026091806102662000_29.1.e302138.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.09.026"},{"key":"2026091806102662000_29.1.e302138.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.01.022"},{"key":"2026091806102662000_29.1.e302138.4","doi-asserted-by":"publisher","DOI":"10.1080\/10550490591003639"},{"key":"2026091806102662000_29.1.e302138.5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.neubiorev.2020.11.025","article-title":"Attention-Deficit\/Hyperactivity Disorder (ADHD), antisociality and delinquent behavior over the lifespan","volume":"120","author":"Retz","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"2026091806102662000_29.1.e302138.6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000487767","article-title":"International Consensus Statement on Screening, Diagnosis and Treatment of Substance Use Disorder Patients with Comorbid Attention Deficit\/Hyperactivity Disorder","volume":"24","author":"Crunelle","year":"2018","journal-title":"Eur Addict Res"},{"key":"2026091806102662000_29.1.e302138.7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/ajad.13133","article-title":"Systematic Review and Meta-Analysis: Treatment of Substance Use Disorder in Attention Deficit Hyperactivity Disorder","volume":"30","author":"Fluyau","year":"2021","journal-title":"Am J Addict"},{"key":"2026091806102662000_29.1.e302138.8","unstructured":"Guideline N . Attention deficit hyperactivity disorder: diagnosis and management. 2021. Available: https:\/\/www.nice.org.uk\/guidance\/NG87 [Accessed 13 Sep 2019]."},{"key":"2026091806102662000_29.1.e302138.9","doi-asserted-by":"publisher","DOI":"10.1177\/0269881114544777"},{"key":"2026091806102662000_29.1.e302138.10","doi-asserted-by":"publisher","DOI":"10.2217\/npy.12.39"},{"key":"2026091806102662000_29.1.e302138.11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jamapsychiatry.2015.41","article-title":"Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit\/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial","volume":"72","author":"Levin","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"2026091806102662000_29.1.e302138.12","doi-asserted-by":"publisher","DOI":"10.1111\/add.12369"},{"key":"2026091806102662000_29.1.e302138.13","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaac.2019.06.012","article-title":"Systematic Review: Nonmedical Use of Prescription Stimulants: Risk Factors, Outcomes, and Risk Reduction Strategies","volume":"59","author":"Faraone","year":"2020","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2026091806102662000_29.1.e302138.14","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1176\/appi.ajp.2018.17091048","article-title":"Prevalence and Correlates of Prescription Stimulant Use, Misuse, Use Disorders, and Motivations for Misuse Among Adults in the United States","volume":"175","author":"Compton","year":"2018","journal-title":"Am J Psychiatry"},{"key":"2026091806102662000_29.1.e302138.15","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S2215-0366(23)00332-2","article-title":"ADHD medication discontinuation and persistence across the lifespan: a retrospective observational study using population-based databases","volume":"11","author":"Brikell","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"2026091806102662000_29.1.e302138.16","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1176\/appi.ajp.2020.20121686","article-title":"Genetic, Clinical, and Sociodemographic Factors Associated With Stimulant Treatment Outcomes in ADHD","volume":"178","author":"Brikell","year":"2021","journal-title":"Am J Psychiatry"},{"key":"2026091806102662000_29.1.e302138.17","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.107.045245"},{"key":"2026091806102662000_29.1.e302138.18","doi-asserted-by":"publisher","DOI":"10.3310\/hta13070"},{"key":"2026091806102662000_29.1.e302138.19","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s00787-019-01325-5","article-title":"Resumption of attention-deficit hyperactivity disorder medication in early adulthood: findings from a UK primary care prescribing study","volume":"28","author":"Newlove-Delgado","year":"2019","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"2026091806102662000_29.1.e302138.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c2582","article-title":"Nested case-control studies","volume":"340","author":"Sedgwick","year":"2010","journal-title":"BMJ"},{"key":"2026091806102662000_29.1.e302138.21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/ebmental-2020-300231","article-title":"Prediction of treatment dosage and duration from free-text prescriptions: an application to ADHD medications in the Swedish prescribed drug register","volume":"24","author":"Zhang","year":"2021","journal-title":"Evid Based Ment Health"},{"key":"2026091806102662000_29.1.e302138.22","unstructured":"World Health Organization . WHO collaborating centre for drug statistics methodology: atc\/ddd index. 2024. Available: https:\/\/atcddd.fhi.no\/atc_ddd_index\/?code=N06BA&showdescription=no [Accessed 04 May 2025]."},{"key":"2026091806102662000_29.1.e302138.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-070744","article-title":"Indications of alcohol or drug use disorders in five different national registers in Sweden: a cross-sectional population-based study","volume":"13","author":"Lundin","year":"2023","journal-title":"BMJ Open"},{"key":"2026091806102662000_29.1.e302138.24","unstructured":"Missbruket, kunskapen, v\u00e5rden (SOU 2011:6): missbruksutredningens forskningsbilaga (offentliga f\u00f6rlaget). 2011."},{"key":"2026091806102662000_29.1.e302138.25","unstructured":"European Union Drugs Agency (EUDA) . Wastewater analysis and drugs \u2014 a European multi-city study. Available: https:\/\/www.euda.europa.eu\/publications\/html\/pods\/waste-water-analysis_en#0-level-9 [Accessed 03 Jun 2025]."},{"key":"2026091806102662000_29.1.e302138.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1995.tb02031.x)"},{"key":"2026091806102662000_29.1.e302138.27","doi-asserted-by":"crossref","first-page":"108186","DOI":"10.1016\/j.drugalcdep.2020.108186","article-title":"Health Literacy among Swedish Patients in Opioid Substitution Treatment: A Mixed-Methods Study","volume":"214","author":"Dahlman","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"2026091806102662000_29.1.e302138.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1203241"},{"key":"2026091806102662000_29.1.e302138.29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/10550490601082783","article-title":"Treatment strategies for co-occurring ADHD and substance use disorders","volume":"16 Suppl 1","author":"Mariani","year":"2007","journal-title":"Am J Addict"},{"key":"2026091806102662000_29.1.e302138.30","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.sapharm.2019.06.001","article-title":"A review of measures used to examine medication adherence in people with ADHD at initiation, implementation and discontinuation of pharmacotherapy","volume":"16","author":"Khan","year":"2020","journal-title":"Res Social Adm Pharm"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2025-302138","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:10:55Z","timestamp":1789737055000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2025-302138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,23]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/bmjment-2025-302138"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2025-302138","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]}}}